HIF1A and ovarian carcinoma: Osada in a recent IHC study (24 patients with ovarian carcinoma stage III/IV patients, 10 of them poorly differentiated G3, followed by cisplatin-based chemotherapy) showed that nuclear HIF1a immunoreactivity was an independent marker of poor prognosis [10].